Aspen operates with an established business presence in approximately 50 countries spanning 6 continents and employs more than 10,000 people. The Group operates 26 manufacturing facilities across 18 sites. Aspen holds international manufacturing approvals from some of the most stringent global regulatory agencies including the FDA, TGA and EMA. Aspen's manufacturing capabilities are scalable to demand and cover a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, APIs and infant nutritionals.
With a market capitalisation of approximately $10 billion, Aspen is the largest pharmaceutical company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies on this exchange. For more information visit: http://www.aspenpharma.com/ [http://www.aspenpharma.com/]
About Swixx BioPharma AG
Swixx now operates fully-owned subsidiaries across Central and Eastern Europe, offering coverage from Moscow to Prague and from Tallinn to Sofia. Net sales in 2019 were 143 million Euros and in 2020 should reach 225 million Euros. Established in 2014, Swixx has gathered outstanding specialty pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. The company specializes in representing research-based pharmaceutical, biotech, orphan, medical equipment and self-care brands. For more info about Swixx, please visit: www.swixxbiopharma.com [http://www.swixxbiopharma.com/] [http://www.amicuspharma.eu/]
 Repici A., Amlani B., Uebel P., Schreiber S. Superior high-quality colon cleansing with 1L NER1006 versus sodium picosulfate + magnesium citrate, 2L polyethylene glycol + ascorbate, or oral sulfate solution: Post hoc pooled analysis of three randomised phase 3 clinical trials. #P0159. Monday 22 October. 12:30 - 13:30 CET. UEGW 2018
 In Austria, Spain and the Netherlands it is known as PLEINVUE(® )rather than PLENVU(®) March 2018. Available at: https://www.medicines.org.uk/emc/medicine/31722. Accessed June 2018.
World Health Organisation. https://www.who.int/news-room/fact-sheets/detail/cancer [https://www.who.int/news-room/fact-sheets/detail/cancer]Last accessed February 2020
 American Cancer Society. https://www.cancer.org/cancer/colon-rectal-cancer/detection-... [https://www.cancer.org/cancer/colon-rectal-cancer/detection-...] Last accessed February 2020
 Bechtold ML, Mir F, Puli SR et al. Optimizing bowel preparation for colonoscopy: a guide to enhance quality of visualization. Ann Gastroenterol 2016; 29: 137 - 146
 Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014; 348: g2467
 Baxter NN, Warren JL, Barrett MJ et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol 2012; 30: 2664 - 2669
Logo -- http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg [http://mma.prnewswire.com/media/597589/Norgine_Logo.jpg]
CONTACT: Media contacts for Norgine: Clara Bentham +44 (0)1895-826654 or+44 (0)7734-367883; Eleni Fistikaki +44 (0)1895-826227 or +44(0)7825-389477; firstname.lastname@example.org; www.norgine.com; Media contacts forFaes Farma: Soraya Gonzalez, email@example.com; Media contacts forAspen: Shauneen Beukes, firstname.lastname@example.org; Media contacts for Swixx:Maja Boskovic. +381-11-4426-321, Maja.Boskovic@swixxbiopharma.com
Web site: https://www.norgine.com//